Health Trials

Nanoliposomal Irinotecan

1

Review clinical trials related to Nanoliposomal Irinotecan. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Dec 24, 2024Locations: 1
Eligibility criteria

Age ≥18, male or female; [+8]

Untreated active CNS metastasis or leptomeningeal metastasis. [+11]

Read more